share_log

復星醫藥:2024年第一次H股類別股東會通告

FOSUN PHARMA: NOTICE OF 2024 FIRST H SHAREHOLDERS CLASS MEETING

HKEX ·  May 24 04:36

Summary by Futu AI

上海復星醫藥(集團)股份有限公司(簡稱「復星醫藥」)將於2024年6月26日舉行2024年第一次H股類別股東會,地點為中國上海市虹許路358號上海天禧嘉福璞緹客酒店。會議將在股東周年大會及A股類別股東會結束後召開,主要議程包括考慮通過關於回購H股及A股股份的一般性授權,以及修訂《公司章程》等事宜。回購股份的目的是為了維護公司價值及股東權益,並將根據中國及香港的相關法律法規進行。回購的H股及A股數量均不得超過已發行總數的10%,且需獲得股東大會的特別決議案通過。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生,非執行董事為陳啟宇先生、姚方先生、徐曉亮先生及潘東輝先生,獨立非執行董事為李玲女士、湯谷良先生、王全弟先生及余梓山先生。
上海復星醫藥(集團)股份有限公司(簡稱「復星醫藥」)將於2024年6月26日舉行2024年第一次H股類別股東會,地點為中國上海市虹許路358號上海天禧嘉福璞緹客酒店。會議將在股東周年大會及A股類別股東會結束後召開,主要議程包括考慮通過關於回購H股及A股股份的一般性授權,以及修訂《公司章程》等事宜。回購股份的目的是為了維護公司價值及股東權益,並將根據中國及香港的相關法律法規進行。回購的H股及A股數量均不得超過已發行總數的10%,且需獲得股東大會的特別決議案通過。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生,非執行董事為陳啟宇先生、姚方先生、徐曉亮先生及潘東輝先生,獨立非執行董事為李玲女士、湯谷良先生、王全弟先生及余梓山先生。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS FIRST CLASS H SHAREHOLDER MEETING ON JUNE 26, 2024 AT THE SHANGHAI TIANHUI JIAFU PUTIK HOTEL, NO. 358 HONGXU ROAD, SHANGHAI, CHINA. The meeting will be held after the end of the Annual General Meeting and the Class A Shareholders' Meeting. The main agenda includes consideration of the adoption of general mandates for the repurchase of H shares and A shares, as well as amendments to the Articles of Association. The purpose of the share repurchase is to preserve the company's value and shareholders' interests and will be carried out in accordance with the relevant laws and regulations of China and Hong Kong. The number of H shares and A shares...Show More
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS FIRST CLASS H SHAREHOLDER MEETING ON JUNE 26, 2024 AT THE SHANGHAI TIANHUI JIAFU PUTIK HOTEL, NO. 358 HONGXU ROAD, SHANGHAI, CHINA. The meeting will be held after the end of the Annual General Meeting and the Class A Shareholders' Meeting. The main agenda includes consideration of the adoption of general mandates for the repurchase of H shares and A shares, as well as amendments to the Articles of Association. The purpose of the share repurchase is to preserve the company's value and shareholders' interests and will be carried out in accordance with the relevant laws and regulations of China and Hong Kong. The number of H shares and A shares repurchased shall not exceed 10% of the total issued and shall be subject to the approval of a special resolution of the General Meeting. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung. The Non-Executive Directors are Mr. Chan Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai. The Independent Non-Executive Directors are Ms. Li Ling, Mr. Tu Tung Leung, Mr. Wang Yuanchi and Mr. Yu Zi Shan.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.